FGFR1 and neoplasm: Theoretically, the case here presented could benefit the most from such treatment, being carrier of two mutations in this cascade, with the somatic PTPN11 variant affecting part of the body—including tumor tissue—and a variant in FGFR1 detected only in tumor tissue.